224 related articles for article (PubMed ID: 34452739)
1. Network Meta-analysis of the Therapeutic Effects of Hypoglycemic Drugs and Intensive Lifestyle Modification on Impaired Glucose Tolerance.
Zhang Y; Fu Y; Mu YM; Huang Y; Xuan J
Clin Ther; 2021 Sep; 43(9):1524-1556. PubMed ID: 34452739
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
[TBL] [Abstract][Full Text] [Related]
3. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; De Grauw WJ
Cochrane Database Syst Rev; 2006 Oct; (4):CD005061. PubMed ID: 17054235
[TBL] [Abstract][Full Text] [Related]
4. Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis.
Gu S; Shi J; Tang Z; Sawhney M; Hu H; Shi L; Fonseca V; Dong H
PLoS One; 2015; 10(5):e0126704. PubMed ID: 25961824
[TBL] [Abstract][Full Text] [Related]
5. [Progress in the prevention of type 2 diabetes].
Schernthaner G
Wien Klin Wochenschr; 2003 Nov; 115(21-22):745-57. PubMed ID: 14743578
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis.
Wang A; Mo T; Li Q; Shen C; Liu M
Endocrine; 2019 May; 64(2):220-232. PubMed ID: 30911997
[TBL] [Abstract][Full Text] [Related]
7. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China.
Pan CY; Landen H
Clin Drug Investig; 2007; 27(6):397-405. PubMed ID: 17506590
[TBL] [Abstract][Full Text] [Related]
8. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
Ratner R; Goldberg R; Haffner S; Marcovina S; Orchard T; Fowler S; Temprosa M;
Diabetes Care; 2005 Apr; 28(4):888-94. PubMed ID: 15793191
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and surgical intervention for the prevention of diabetes.
Chiasson JL
Nestle Nutr Workshop Ser Clin Perform Programme; 2006; 11():31-42. PubMed ID: 16820729
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
[TBL] [Abstract][Full Text] [Related]
11. A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance.
Josse RG; McGuire AJ; Saal GB
Int J Clin Pract; 2006 Jul; 60(7):847-55. PubMed ID: 16858756
[TBL] [Abstract][Full Text] [Related]
12. The potential of metformin for diabetes prevention.
Slama G
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S104-11. PubMed ID: 14502107
[TBL] [Abstract][Full Text] [Related]
13. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Ratner RE; Christophi CA; Metzger BE; Dabelea D; Bennett PH; Pi-Sunyer X; Fowler S; Kahn SE;
J Clin Endocrinol Metab; 2008 Dec; 93(12):4774-9. PubMed ID: 18826999
[TBL] [Abstract][Full Text] [Related]
14. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.
Goldberg RB; Temprosa M; Haffner S; Orchard TJ; Ratner RE; Fowler SE; Mather K; Marcovina S; Saudek C; Matulik MJ; Price D;
Diabetes Care; 2009 Apr; 32(4):726-32. PubMed ID: 19171717
[TBL] [Abstract][Full Text] [Related]
15. Reflecting on type 2 diabetes prevention: more questions than answers!
Rosenstock J
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():3-11. PubMed ID: 17877541
[TBL] [Abstract][Full Text] [Related]
16. The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial.
Guardado-Mendoza R; Salazar-López SS; Álvarez-Canales M; Farfán-Vázquez D; Martínez-López YE; Jiménez-Ceja LM; Suárez-Pérez EL; Angulo-Romero F; Evia-Viscarra ML; Montes de Oca-Loyola ML; Durán-Pérez EG; Folli F; Aguilar-García A
Metabolism; 2020 Mar; 104():154054. PubMed ID: 31887309
[TBL] [Abstract][Full Text] [Related]
17. Identification and treatment of prediabetes to prevent progression to type 2 diabetes.
Fonseca VA
Clin Cornerstone; 2007; 8(2):10-8; discussion 19-20. PubMed ID: 18357952
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Scheen AJ
Drugs; 2003; 63(10):933-51. PubMed ID: 12699398
[TBL] [Abstract][Full Text] [Related]
19. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.
Palmer AJ; Roze S; Valentine WJ; Spinas GA; Shaw JE; Zimmet PZ
Clin Ther; 2004 Feb; 26(2):304-21. PubMed ID: 15038953
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
